Jennison Associates
NXTM

Jennison Associates’s NxStage Medical Inc. NXTM Stock Holding History

Jennison Associates’s Portfolio NXTM Stock Details NXTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-48,901
Closed -$1.23M – 713
2017
Q2 		$1.23M Sell
48,901
-602,321
-92% -$14.9M ﹤0.01% 563
2017
Q1 		$17.5M Sell
651,222
-676,951
-51% -$18.7M 0.02% 436
2016
Q4 		$34.8M Buy
1,328,173
+21,686
+2% +$536K 0.04% 323
2016
Q3 		$32.6M Sell
1,306,487
-208,990
-14% -$4.87M 0.04% 341
2016
Q2 		$32.9M Sell
1,515,477
-189,133
-11% -$3.37M 0.04% 350
2016
Q1 		$25.6M Buy
1,704,610
+309,436
+22% +$5.19M 0.03% 379
2015
Q4 		$30.6M Buy
1,395,174
+345,394
+33% +$6.44M 0.03% 367
2015
Q3 		$16.6M Buy
1,049,780
+112,792
+12% +$1.81M 0.02% 460
2015
Q2 		$13.4M Buy
936,988
+360,316
+62% +$6.1M 0.01% 499
2015
Q1 		$9.98M Buy
+576,672
New +$10.2M 0.01% 496

Other funds holding NXTM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PCM
Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Jennison Associates's NXTM Position: Q3 2017 in Review

Jennison Associates sold out of NxStage Medical Inc. (NXTM) in Q3 2017, closing a stake of 48,901 shares — an estimated $1.23M sold.

Jennison Associates first reported a position in NXTM in Q1 2015 and held it in 10 quarters. The position peaked at $34.8M in Q4 2016. 168 funds tracked by Wall St. Rank hold NXTM as of Q3 2017.

  • Jennison Associates reported no remaining NxStage Medical Inc. position as of Q3 2017 after selling out during the quarter.
  • Jennison Associates sold 48,901 NxStage Medical Inc. shares in Q3 2017, an estimated $1.23M.
  • Jennison Associates first reported a position in NxStage Medical Inc. in Q1 2015 and held it in 10 quarters.
  • Jennison Associates's NxStage Medical Inc. position peaked at $34.8M in Q4 2016.
  • 168 funds tracked by Wall St. Rank held NxStage Medical Inc. as of Q3 2017.

Based on Jennison Associates's 13F filing for Q3 2017, filed 3 Nov 2017.